The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.
Grażyna SygitowiczAgata Maciejak-JastrzębskaDariusz SitkiewiczPublished in: Biomolecules (2021)
Galectin-3 plays a prominent role in chronic inflammation and has been implicated in the development of many disease conditions, including heart disease. Galectin-3, a regulatory protein, is elevated in both acute and chronic heart failure and is involved in the inflammatory pathway after injury leading to myocardial tissue remodelling. We discussed the potential utility of galectin-3 as a diagnostic and disease severity/prognostic biomarker in different cardio/cerebrovascular diseases, such as acute ischemic stroke, acute coronary syndromes, heart failure and arrhythmogenic cardiomyopathy. Over the last decade there has been a marked increase in the understanding the role of galectin-3 in myocardial fibrosis and inflammation and as a therapeutic target for the treatment of heart failure and myocardial infarction.
Keyphrases
- heart failure
- left ventricular
- acute ischemic stroke
- oxidative stress
- cardiovascular disease
- cardiac resynchronization therapy
- type diabetes
- atrial fibrillation
- pulmonary hypertension
- acute heart failure
- metabolic syndrome
- risk assessment
- small molecule
- drug induced
- ejection fraction
- combination therapy
- aortic dissection
- replacement therapy